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INTRODUCTION 
OBESITY 
 Overweight and Obesity is measured by Body Mass Index (BMI) through 
calculated as weight divided by height squared (Sivakumar et al., 2016). 
Definitions  
Overweight was defined as a BMI ≥23 kg/m2 but <25 kg/m2 for both genders 
(based on the World Health Organization Asia Pacific Guidelines) with or without 
Abdominal Obesity (AO). Generalized Obesity (GO) was defined as a BMI ≥ 25 
kg/m2 for both genders (based on the World Health Organization Asia Pacific 
Guidelines) with or without AO. AO was defined as a Waist Circumference (WC) ≥ 
90 cm for men and ≥ 80 cm for women with or without GO. Isolated Generalized 
Obesity (IGO) was defined as a BMI ≥ 25 kg/m2 with waist circumference of < 90 cm 
in men and < 80 cm in women. Isolated Abdominal Obesity (IAO) was defined as a 
WC of ≥ 90 cm in men or ≥ 80 cm in women with a BMI< 25 kg/m2. Combined 
Obesity (CO): Individuals with both GO and AO. Non obese subjects: Individuals 
without either GO or AO (Pradeepa et al., 2015). 
Classification 
 Based on degree of obesity they are classified into three types as follows. 
Class I Obesity       -  BMI with 30 to 34.9 kg/m2 
Class II Obesity -  BMI with 35 to 39.9 kg/m2 
Class III Obesity -  BMI with more than 40 kg/m2 (Sunyer et al., 
2002). 
Over the past 25 years prevalence of overweight and obesity has been increase 
worldwide concern of alarming proportion. According to World Health Organization 
(WHO) 2015, it shows overweight and obese people population were occupied by one 
third of world portion. Among the global hazards top 10 countries which contain more 
number of obese people, India is just behind United States and China. In India the 
occurrence of obesity were high in Tamilnadu (Sivakumar et al., 2016, Pradeepa et 
al., 2015). 
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 At present, half or more individuals is now identified as overweight or obese 
were belongs to the countries involved in Organization for Economic Co-operation 
and Developement (OECD, Rukhsana et al., 2012). More than 90% of overweight or 
obese having type 2 diabetes in US (Lloret-Linares et al., 2008). Every year 3 lakhs 
adults were died due to these complications. Obesity and diabetes are the leading 
disorders which cause major fatal complications including hypertension, stroke, heart 
disease, high cholesterol, osteoporosis, Alzheimer’s disease and certain types of 
cancers (Song et al., 2014). The projected diabetes could be raise from 171 million in 
2000 to 366 million in 2030 including developed and developing countries (Modak et 
al., 2011).   
Obesity is a common health disorder of carbohydrate and lipid metabolism due 
to multiple factor contributing to increased risk of type 2 diabetes, blood pressure, 
cardio vascular disorder, non alcoholic fatty liver metabolic disorder, stroke and 
certain cancer is the major cause for morbidity and mortality which could be 
associated with obesity. Since the etiology of obesity is multifactorial, the sedentary 
life styles, lack of physical exercise, particularly consumption of energy rich diets are 
play an important role for its development (Sudhakara et al., 2016). Individual’s body 
weight increase with above 20% ideal weight shows adverse clinical consequences of 
obesity (Camila et al., 2006, Von Diemen et al., 2006). Thus currently obesity is a 
major health problem. Therefore it is important to maintain healthy life of obese 
person by the prevention of obesity. 
Strategies involved in management of weight reduction in obese people, which 
includes diet control, exercise, pharmacological treatment, behavioural therapy and 
bariatric surgery or its combination with one another. Exercise, behavioural therapy 
and diet control were the first line treatment for overweight and obesity. Even safest 
method of management of obesity these are difficult to maintain for long time. 
Pharmacological treatment on reducing body weight may involves either by  
decreasing appetite or increase satiety, and also through reducing absorption of 
nutrient or enhance the utilization of energy. Though medications are available but 
these are having poor outcomes on long term weight management and are 
accompanied with multiple adverse effects. Bariatric surgery, generally used for obese 
individuals with BMI nearly or greater than 40 kg/m2. This is effective for sustaining 
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the weight loss but often it may leads to complications such as increased mortality 
(Sivakumar et al., 2016).  
The year 2013 could be the landmark for the field of obesity, because June 
2013 American Medical Association recognizes obesity as a disease. With respect to 
future point of view, obesity is set to be the world’s main cause for morbidity and 
mortality on 21st century (Parveen and Uma, 2015).  Thus, there is an essential need 
of alternate therapy which provides moderate weight loss in overweight or obese with 
an effective and safety of obesity for reducing the fatal complications. 
DISEASE ASSOCIATED WITH OBESITY (Sunyer et al., 2002) 
 Insulin resistance / hyperinsulinemia     
 Type 2 diabetes 
 Hypertension     
 Dyslipidemia  
 Coronary heart disease   
 Gallbladder disease   
 Cancer (prostate, endometrial, uterine, cervical, ovarian, colon, 
kidney, gallbladder, and postmenopausal breast) 
 Premature death    
 Psychological distress 
 Osteoarthritis 
 Stroke 
 Asthma 
 Sleep apnoea 
 Complications of pregnancy 
 Menstrual irregularities 
 Hirsutism 
 Increases surgical Risk 
Insulin Resistance / Hyperinsulinemia  
 A decrease in sensitivity to insulin can occur as consequence of obesity. 
Impact of obesity is independent of genetic factor. An obese individual has higher 
fasting insulin levels as compared with non-obese member which shows that lower 
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insulin sensitivity on 75 gm oral glucose tolerance test. Once insulin resistance and 
hyperinsulinemia is occurred, it initiates metabolic changes to cause diabetes, 
hypertension, heart disease and dyslipidemia. BMI is inversely proportional to insulin 
sensitivity. 
Type 2 Diabetes 
 The risk of type 2 diabetes increases with increasing BMI. Weight gain is a 
significant determining risk of diabetes, selectively individuals with higher baseline 
BMI. In AO, waist to hip ratio is a strong predictor of diabetes than BMI alone. 
Subjects with low waist to hip ratio have decreased chance of developing diabetes 
than highest BMI. The risk of developing diabetes was 30 times higher than with 
increased BMI. Hence, type 2 diabetes is proportionally correlated with BMI. 
Hypertension 
 The relative risk of developing hypertension also increases steeply with 
increasing BMI. The relative risk on BMI of 32 kg/m2 or greater has been 4.8. In 
addition to BMI, weight gain also significantly increased risk of hypertension due to 
inadequate blood supply to all parts of the body and reduction in body weight could 
reduce such risk. A person with BMI of 30 kg/m2 or higher were twice as likely to 
have hypertension as compared with normal individuals. The Third National Health 
and Nutrition Examination Survey (NHANES III) data also prove that obesity 
enhances risk of hypertension. There are multiple mechanisms were involved in the 
development of hypertension in obese people: increased renal absorption of sodium 
and water, activation of sympathetic nervous system, alteration in Na+/H+ - ATPase 
activity. 
Dyslipidemia 
 Increased hepatic glucose output is not only the consequences of increasing 
Free fatty acid (FFA) levels in obesity.  Higher FFAs also influence the lipid 
metabolism by enhancing the production of Very Low Density Lipoprotein (VLDL) 
by the liver, decreasing High Density Lipoprotein (HDL) levels and also promoting 
the production of most small, dense Low Density Lipoprotein (LDL) particles. These 
alterations occur in lipoprotein profile are associated with increased risk of congestive 
heart disease. The impact of obesity on lipid metabolism was higher as compared with 
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non obese subjects. In addition to that increased synthesis of triglycerides was also 
occurred in obese individuals. 
Congestive Heart Disease  
 A relationship between obesity and Congestive Heart Disease (CHD) mortality 
was explained in the Nurses’ Health Study. The relative risk of developing CHD 
death increased significantly with increasing BMI. Obese individuals with BMI of 
29.0 to 31.9 kg/m2 and 32.0 kg/m2 or higher were at 4.6 and 5.8 times greater risk, 
correspondingly than those with BMI under 22.0 kg/m2. However, the waist-to-hip 
ratio was strongly projecting the CHD mortality. Obese people with increased waist-
to-hip ratio had a increasing relative risk of CHD death of 8.7 compared with those in 
the lowest waist to hip ratio. 
Gall Bladder Disease 
An independent relationship between obesity and gall bladder disease was 
shown by atherosclerosis risk in communities study. The risk of gallbladder disease 
was increased with increasing BMI those with greater than 25 kg/m2 as well as 
influenced by increased waist to hip ratio. Gall bladder diseases were generally 
occurring higher in obese women than male. 
Cancer 
The relative risk of developing cancer also increases steeply with increasing 
BMI. Mortality rates of cancer was highest among than those who were overweight. 
The major impact of obesity on cancer was estimated by utilizing the prospective 
study. From this study mortality ratios for colorectal and prostate cancer in men and 
endometrial, uterine, cervical, ovarian, gallbladder, and breast cancer in women were 
observed. Cancer death rate of BMI who has more than 32 kg/m2 were twice that of 
those BMI less than 19 kg/m2. The increased death rate was predominantly because of 
higher mortality caused by colorectal, breast and endometrial cancers. 
The other minor disorders caused by overweight and obesity are Premature 
death, Psychological distress, Osteoarthritis, Stroke, Asthma, Sleep apnoea, 
Complications of pregnancy, Menstrual irregularities, Hirsutism and Increases 
surgical risk. 
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DRUGS FOR OBESITY 
 Number of drugs has been approved for the treatment of obesity on past 2 
decade. Currently, there are only few weight-loss drugs with a favourable side effect 
profile available. However, most of them have been withdrawn from the market 
because of their severe adverse effects, leaving only Orlistat, a lipase inhibitor. Drugs 
like Rimonabant have been promising in the recent past. However, severe side effects 
lead to their withdrawal from the market. Presently, GLP-1 (Glucagon Like Peptide-1) 
analogues such as Liraglutide are being promoted as a new strategy to loose weight 
without major side effects however at high costs (Seifarth et al., 2013).  
Orlistat 
 Orlistat was approved by the Food and Drug Administration (FDA) in 1998 
and is the currently available drug for long term therapy of obesity. Orlistat is an 
effective and reversible gastric and pancreatic lipase inhibitor preventing dietary fat 
absorption by approximately 30% , has been used for around two decades and proved 
to be useful in improving weight loss and weight maintenance. The beneficial effect 
on body weight is significant with improve number of cardio metabolic parameters, 
including WC, blood glucose levels, blood pressure and lipid profiles. Treatment with 
Orlistat was associated with improving cardiovascular risk after adjustment for weight 
loss. In addition to that Orlistat shows significant decrease in total cholesterol and also 
reducing the incidence of diabetics. 
Although Orlistat has approved by FDA, studies showed it causes undesirable 
adverse effects, and severe health risks. The frequently experienced side effects are 
gastrointestinal and include diarrhea, flatulence, bloating, abdominal pain, dyspepsia 
and recently severe liver injury also has been reported. Current study also stated that 
the modest efficacy, undesirable adverse effects, and severe health risks combine to 
highlight the deficiencies of Orlistat and underscore the pressing need for alternate 
therapy for anti-obesity drug options (Sivakumar et al., 2016, Kang et al., 2012) 
GEOMAGNETIC FIELD 
As one of the physical factors of environment, like air pressure and 
temperature, Geomagnetic Field (GMF) 30-70 µT (micro Tesla) plays an important 
role on living and evolution for organism on earth (Lohmann, 2010 and ICNIRP 
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Guidelines, 2009). All living being are sensitive to magnetic field. This can be 
possible by two mechanism due to presence of magnetic nanoparticle like Fe3O4 
(magnetite) and also influenced by chemical reaction occur in living organism. 
Living things such as human beings, animals, plants and micro organisms 
which are born and grow under the presence of several physical fields including 
geomagnetic fields. In some way, living beings are affected by the physical 
characteristics of the GMF, because of their long time of relationship with GMF due 
to their sensitivity. The first experimental evidence of living beings can be influenced 
by the GMF was the discovery of magnetotactic bacteria in 1963 by Salvatore Bellini 
and later by Blakemore in 1975. GMF is not fully dipolar. But some areas on the 
Earth’s surfaces were expected from a dipolar one (Belova and Acosta-Avalos, 2015). 
The idea of electromagnetic fields in medical research was firstly given by 
Kolin and later Korchevskii and Marochnik (Kolin, 1936). 
BIOEFFECTS OF MAGNETIC FIELD 
Bioelectromagnetics is the study of interaction between non-ionizing 
electromagnetic field and biological system. In recent year several studies have 
suggested, possible bioeffect of magnetic fields on rodent. Application of magnetic 
field to treat disorder in human is one of the most promising complementary / 
alternative and conventional medicines. Since it provide non invasive, easy and 
safety. In fact, ancient China, Japan, and Europe use natural magnetic material to treat 
disease such as headache, oedema, and rheumatism, but also cure paralysis. The 
mechanism of treating disorders may be mediated by stimulation of increased blood 
due to alteration of calcium ion in muscle. 
 Past few decades hundreds of experiments have been carried out on animal to 
asses biological effect of exposure on different types of magnetic field such as 
permanent/ Static magnetic field (SMF), low frequency sine waves, Pulsed frequency 
electromagnetic field (PEMF), Radio frequency electromagnetic field (RF-EMF), 
transcranial electric/magnetic stimulation. In this, SMF of various types were included 
in this studies due to most of the work performed on these types of magnetic field 
while, others are excluded from this studies due to deficiency of data. Results 
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obtained from these studies shows most has beneficial effect and some has negative 
effect. 
 Under these conditions most experimental results carried over year for 
bioeffect of different magnetic field on rodents. Because rodents are similar in genetic 
resemble with human as well as some advantage in reproducibility and also well 
developed disorder model with low cost. To the best knowledge experiment on effect 
of various magnetic fields were rapidly increased after the Second World War 
(Markov, 2007). 
 Numerous publications discussed the possibilities of exogenous magnetic to 
initiate beneficial effect on various biological processes, which are importance for 
healing of different injuries and pathologies. Their results are discussed in table 3.1 
and 3.2. According to their frequency, electromagnetic fields are classified into four 
types by European commission of non ionization radiation, which are mentioned in 
table 1. They are SMF, low frequency magnetic fields, intermediate frequency 
magnetic fields, RF-EMF (Lewczuk et al., 2014). 
Table 1: Types of Magnetic Field and their frequency 
S.No TYPES OF MAGNETIC 
FIELD 
FREQUENCY 
RANGE 
1. Static magnetic field 0HZ 
2. Low frequency magnetic 
field 0-300HZ 
3. Intermediate frequency 
magnetic field 300HZ-100KHZ 
4. Radio frequency 
electromagnetic field 100KHZ-300GHZ 
 
Corresponding to therapeutic utility SMF is mainly discussed due to numbers 
of availability of results and focused on them to show integrated concept on biological 
system. Low frequency sine wave and transcranial magnetic stimulation are excluded 
due to data deficiency. Here we give brief introduction for static magnetic field on 
their bioeffect and more detailed sub types explained individually on their following 
topic. 
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Static Magnetic Field: 
 SMF can be created by various permanent magnets as well as by passing direct 
current through a coil (Markov, 2007). It can be characterized by frequency of (zero) 
0 Hz and not varying with time during production of magnetic field (Elferchichi et al., 
2011). Bioeffect of SMF on animal model since 1948 (Yu and Shang, 2014). Due to 
development of animal model for various disorders, examination on bioeffect of 
magnetic field rapidly increased. 
 SMF have different therapeutic effect in animals including anti inflammatory, 
pain relive, antibacterial effect, but SMF also have therapeutic effect in different 
system of rodent has been examined , which are seen in table 3 (Yadollahpour and 
Rashidi, 2014). The application of SMF has increased for treating some specific 
medical problems during last three decades. SMF can be easily penetrated into 
biological tissue through several physical mechanisms. So that SMF are widely used 
throughout the world (Lahbib et al., 2010). Several clinical studies are described in 
table 3.1 and 3.2. Due to diverse response is of SMF on biosystem of living organism, 
it can be classified as various intensity ranges are mentioned in table 2. 
The application of permanent magnets for treating specific medical problems 
such as arthritis, chronic pain syndromes, wound healing, insomnia, headache and 
others has steadily increased during the last decade (Colbert et al., 2009). 
Table 2: Types of SMF and its intensities (Elferchichi et al., 2010) 
S.NO SMF 
INTENSITY RANGE 
(mT-milli Tesla, T-Tesla) 
1. Weak intensity Less than 1mT  
2. Moderate intensity 1mT – 1T  
3. Strong intensity 1T – 5T 
4. Ultra strong intensity More than 5T 
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Table 3.1: Bioeffects of Static Magnetic Field 
TYPES 
OF SMF 
BIOLOGICAL 
EFFECT 
EXPOSURE 
PARAMETERS REFERENCE 
Weak 
Intensity 
SMF 
Decrease volume of 
tumour and increase 
longevity 
Mice  - 42µT, 1h a day for 
12 days 
Novikov et al., 
2009 
Influence of action on 
pineal gland Rats – 80µT, 1h 
Lerchl et al., 
1991 
Moderate 
Intensity 
SMF 
 
Cause temporary 
diabetic like state 
Rats – 1mT/10mT, 
1h a day for 10 days 
Gorczynska 
and 
Wegrzynowicz
, 1991 
Changes occur in 
haematological and 
biochemical parameter 
Rats – 128mT, 1h a day for 
5/30 days 
Amara et al., 
2006b 
Alteration in glucose 
and lipid metabolism 
Rats – 128mT, 1h a day for 
5/15 days 
Lahbib et al., 
2010 
Changes in glucose and 
lipid parameters of 
Serum and skeletal 
muscle 
Rats – 128mT, 1h a day for 
15 days 
Elferchichi et 
al., 2010  
Anti oxidant activity Rats – 128mT, 1h a day for 30 days 
Ghodbane et 
al., 2011b 
Biochemical parameters 
change due to up 
regulation of 
norepinephrine 
concentration 
Rats - 128mT, 1h a day for 
5 days 
Abdelmelek et 
al., 2006 
Increasing immune 
function 
Mice - 200-400mT, until 
death 
Yang et al., 
2009 
Changes occur in 
behavioural response 
Rats - 128mT, 1h a day for 
5 days 
Ammari et al., 
2008 
Alteration of inorganic  
ion content in spinal 
cord, medulla 
Same as above Miryam et al., 2010 
No influence on 
spermatogenesis 
Rats - 128mT, 1h a day for 
30 days 
Amara et al., 
2006a 
Antidiabetic effect 
Diabetic mice - 2.8 to 
476.7mT, 30 min a day for 
12 weeks 
Laszlo  and 
Porszasz et al., 
2011 
Produce Analgesic 
effect due to alteration 
in blood circulation 
Rats - 200 mT for 4 weeks 
Kanai and 
Taniguchi et 
al., 2012 
Anti oxidative function 
on blood 
Rats - 128 mT, 1h a day for 
5 days 
Ghodbane S et 
al., 2011a 
Alters blood pressure 
associated with 
Nicardipine 
Rats - 180 mT, 1h a day for  
8/6 weeks 
Okano and 
Ohkubo, 2005, 
2006 
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Weak Intensity SMF  
 SMF produced is less than 1mT known as weak intensity SMF. This intensity 
magnetic field also expressed as µT (micro Tesla) range. Normal metabolisms in 
living organism are occurred, which are frequently exposed to this intensity range 
because of geomagnetic field 50µT (ICNIRP, 2009). Apart from that only limited 
numbers of studies are carried out by using weak intensity SMF.  
Moderate Intensity SMF  
 Moderate intensity SMF is characterized by permanent magnet which 
produces the magnetic field limit of 1mT-1T. Normal whole human body safety 
exposure limit were set up to 400mT of moderate intensity SMF (ICNIRP, 2009). 
Number of the studies were conducted between these exposure limit cause biological 
effects on most of the system in rodents. According to researchers (Gorczynska and 
Wegrzynowicz 1991, Elferchichi et al., 2011, Laszlo et al., 2011, Amara et al., 2006, 
Elferchichi et al., 2010, Lahbib et al., 2010), experiment conducted by using magnetic 
field less than 200mT is suitable for metabolic alteration in living organism. In the 
past decade, there has been substantial and growing evidence that moderate intensity 
Static magnetic fields (SMF) ranging 1mT-1T (Rosen, 2010) can influence 
physiological processes. 
Strong Intensity SMF  
Strong intensity SMF is characterized by permanent magnet which produce 
magnetic field from 1T to 5T. During past few decades only limited number studies 
are carried on this type SMF to express their bioeffect on rodent. 
Ultra Strong Intensity SMF  
This type of SMF can be categorized based on magnetic field intensity more 
than 5T produced by permanent magnet. During past 30 years least number of studies 
is conducted on this type of SMF. 
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Table 3.2: Bioeffects of Static Magnetic Field 
TYPES 
OF SMF 
 
BIOLOGICAL EFFECT EXPOSURE PARAMETERS REFERENCE 
Strong 
Intensity 
SMF 
 
Decrease food and water 
consumption, decrease in 
body weight 
Mice - 5T for 24h, 48h Tsuji et al., 1996 
Alteration in pain response Mice - 3T for 30 min Laszlo and Gyires, 2009 
Changes occur in primary 
bone marrow  cells Mice - 1.4T for 1h Bhatia, 1999 
No changes observed in 
treated and control group Mice - 4.7T for 2 days 
Okazaki et al., 
2001 
Alteration in bone marrow Mice - 3T, 4.7T for 3 days 
Suzuki et al., 
2001 
Activation of intracellular 
signalling transduction 
pathways 
Rats- 1T for 1h Prina-Mello et 
al., 2006 
Ultra 
Strong 
Intensity 
SMF  
Change in locomotors 
activity 
Rats - 14.1T for 30/5 
min 
Houpt et al., 
2007, 2011 
Behavioural changes Rats - 14T for 30 min Cason et al., 2006 
Changes blood flow Rats - 8T for 5 min Ichioka et al., 2003 
Changes behaviour 
response Rats - 7T for 30 min 
Houpt et al., 
2003 
No changes observed Rats - 9.4T for 10 
weeks 
High et al., 
2000 
Effects on sciatic nerve Rats - 8T for 1ms Sekinz et al., 2006 
 
ORAL HYPOGLYCAEMIC AGENT  
Oral hypoglycaemic agent is used for reducing raised blood glucose in type 2 
diabetic patient. Several types of oral hypoglycaemic agents are associated with 
increased body weight, including insulin secretagogues (sulphonylureas and  
meglitinides) and  thiazolidinediones (TZDs). Two classes of oral hypoglycaemic 
agents have not been associated with weight gain: the biguanides (of which 
Metformin is now effective) and α-glucosidase inhibitors (Golay, 2008).  
Metformin is one among the oldest oral hypoglycaemic medications not only 
reduces type 2 diabetes but also produces modest and durable weight loss effect 
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among the other pharmacological agents in  diabetic patients and it has been also 
shows weight loss in obese non diabetic populations.  Several randomized studies 
reported that Metformin has neutral effect on weight gain (Priscilla, 2007). It is 
frequently chosen for well tolerated and for not causing hypoglycaemia. Furthermore, 
Metformin is the only oral antidiabetic drug that was proven to reduce cardiovascular 
risk (Mitri and Hamdy, 2009). Studies on Metformin were reported that, it shows 
beneficial effects in correcting disturbances in lipid metabolism in individuals. 
Metformin is reported to have beneficial effect in weight reduction of obese diabetic 
patients and high fat diet induced overweight in wistar rats. It is also commonly 
prescribed for patients with polycystic ovary syndrome and its use resulted in weight 
reduction. Further use of Metformin is reported to show protective action against 
obesity associated Non-Alcoholic Fatty Liver Disease (NAFLD), hepatic steatosis, 
kidney and cardiovascular problems (Golay, 2008 & Sudhakara et al., 2016). 
Metformin causes weight loss by decreasing food intake. Metformin primarily 
acts on the central nervous system to reduce appetite by attenuating hypothalamic 
Adenosine Monophosphate-activated Protein Kinase (AMPK) activity, which 
decreases Neuropeptide Y (NPY, Orexigenic) and increases Proprio Melano Cortin 
(POMC, Anorectic) expression. In addition to that Metformin has food lowering 
effects by increasing leptin and insulin sensitivity, improving GLP-1 levels, and 
affecting gut flora. It also reduces ectopic lipid depots (i.e. liver and skeletal muscle) 
through increased fat oxidation and decreased lipid synthesis, which may be regulated 
to some extent by circadian clock genes (Malin and Kashyap , 2014). 
Recently studies also shown, it is involved in energy expenditure and body fat 
mass regulation and effectively controls weight gain, obesity and associated heart 
disease. In the United Kingdom Prospective Diabetes Study (UKPDS), Metformin did 
not cause change in body weight after 3 years of regular use (Mitri and Hamdy, 2009). 
Based on literature and to compensate the SMF induced side effects, we aimed 
to evaluate the efficacy and safety of Metformin and SMF alone and the effect of 
combination therapy on High Fat Diet (HFD) induced overweight and compare them 
with standard anti-obesity i.e., Orlisat of both on lipid profiles and liver function 
parameters, blood glucose level, body weight, food & water intake, body temperature 
and locomotor activity of control and experimental rats. 
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REVIEW OF LITERATURE 
A review of revealed literature is an fundamental aspect of scientific research. 
It involves the systematic detection, scrutiny and outline of written material that 
contains information on a research problem. It broadens the understanding and gain an 
insight of a wide conceptual content into which the problem fits. 
Weak Intensity Static Magnetic Field: 
 Novikov  et al., 2009 have used an experimental model of carcinoma 
bearing mice to examine the effect of weak intensity SMF. Particularly 
weak intensity SMF exposed to normal animal shows no harmful 
effects on major organs and tissue. In addition, no pathological 
deviations were observed. Weak intensity SMF exposed on 
experimental model of carcinoma bearing mice cause degradation of 
tumor size initiated by autolytic enzyme and then cells are lysed. 
Simultaneously it activates antitumor immunity; particularly it 
stimulates the production of tumor necrosis factor this leads to elevate 
the level of local concentration of reactive oxygen species. There by 
producing anticancer activity. Finally the result showed that exposed 
mice had a decrease the incidence of tumor growth and an increase in 
longevity.   
 
 Research by Lerchl et al., 1991 have suggested that application of 
80µT SMF cause effect in mammalian pineal gland. Because pineal 
gland is sensitive to magnetic field of spatial orientation. Based on 
their finding the result suggested that artificial SMF cause change in 
pineal Indole metabolism. When a tissue exposed to altered magnetic 
field cause production of eddy current. An induced eddy current may 
affect nervous system. 
Moderate Intensity Static Magnetic Field: 
 Gorczynska and Wegrzynowicz, 1991  have researched the biological 
effect of SMF on rats exposed to 1mT and 10mT. The data showed 
that, it cause temporary diabetic like state due to hyper function of 
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adrenal, thyroid and pituitary glands and also pancrease. Hence, the 
release of insulin got decreased while glucagon content was increased. 
It seems that metabolism of glucose is similar to diabetics. It has been 
suggested that reduction of insulin release may be decrease in calcium 
efflux of islet cell caused by magnetic field. Further magnetic field 
creates hydrophobic property of cell membrane and this will affect the 
glucose transport across cell membrane.  
 
 Elferchichi et al., 2010 concluded that there were significant difference 
in treated and control group after exposure to 128mT SMF using rat. 
This shows prediabetic like state, when metabolic alteration were 
induced by moderate intensity SMF could develop. Moreover, it is 
important to note that hyperglycemia due to conformational changes 
occur in insulin by magnetic field exposed animals. It will leads to 
reducing the binding capacity of insulin particularly at hepatocytes and 
results in hyperglycemia. Additionally, raised in blood glucose also 
caused by epinephrine.  
 
 Study conducted by Laszlo et al., 2011 observed the decrease in blood 
glucose level on repeated exposure of moderate intensity SMF in 
diabetic mice. This indicating the promising application of SMF for 
future treatment subsequently this study shows improved diabetic 
wound healing rate. From the above studies both positive and negative 
effects in glucose metabolism influenced by SMF, because it was 
based on magnetic field strength. 
 
 Amara et al., 2006b conducted an experiment on rat blood which is 
exposed to 128mT intensity. Sub acute exposure of SMF reduces body 
weight of animal and the same treatment will cause increase of white 
blood cells, red blood cells, platelets and haemoglobin concentration 
while hematocrit level unchanged. This could be probably due to 
hypoxia status. Whereas increased in blood glucose level observed in 
magnetic field exposed rat could be related to the structural and 
functional changes in pancrease. The results were shows that alteration 
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in haematological and biological parameter due to proliferation of 
blood cells and enzymes release in blood related to duration of 
exposure.  
 
 Similar work has been carried out by Ghodbane et al., 2011a in 
addition with selenium were included in their study. Because magnetic 
field treatment reduces selenium in major organs like kidney, brain and 
muscle. Hence combine effect of selenium and SMF should increases 
the antioxidant activity minimize the oxidative stress which is induced 
by SMF in rat.  The result proposed by means of examine the 
antioxidant materials like tochopherol, retinol, glutathione peroxidise.  
 
 Lahbib et al., 2010 Elferchichi et al., 2010 observed the glucose and 
lipid parameters (glucose, cholesterol, phospholipids, triglycerides,) in 
serum and skeletal muscle, and also glycogen content in liver and 
muscles by using rat as an experimental model  exposed to moderate 
intensity SMF of 128mT. This cause hyperglycaemia attributed due to 
increased release of hyperglycaemic hormone (glucagon) and/or 
inhibition of hypoglycaemic hormone (insulin). Whereas lipid 
metabolism also altered because of membrane integrity. The decrease 
of body weight might be due to reduction in body fluid and protein 
content including hormonal changes and relatively loss in liver weight 
were also observed. In tissues, SMF exposure showed significant 
alteration in enzyme activities. The data showed that SMF effects on 
glucose and lipid metabolism and in addition, the conducted 
investigation on rat to examine the effect of SMF on loss in body 
weight. Therefore moderate intensity SMF seems to have anti-obese 
effect.  
 
 A study was carried out by Abdelmelek et al., 2006 on skeletal muscle 
of rats were induced by moderate intensity SMF for 5 days. The result 
showed that 128mT cause effects in regulation of norepinephrine 
concentration. This may affect increase in blood pressure but no 
changes were observed in growth rate. The basic mechanisms involved 
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in changing the norepinephrine concentration were caused by magnetic 
field of electro sensitive ion channels on plasma membrane. 
 
 Yang et al., 2009 have used an experimental model of mice to examine 
the effects of moderate intensity SMF. Mechanism of antitumor 
activity may be mediated by enhancing the cell proliferation and 
decreasing the affected cell number significantly. The findings 
suggested that, life time was prolonged significantly in leukaemia 
infected mice by upregulating the function of immune system for 
certain period of time.  
 
 Amara et al., 2006a studied the sub chronic effect of SMF exposure on 
testicular function by examine the sperm count, genital organ weight 
and sperm motility. Finally they concluded that there were no 
significant changes occur between control group and treated group on 
spermatogenesis in rat testes. 
  
 Ammari et al., 2008 studied the relationship of rat behavioural 
response and moderate intensity SMF using 128mT fields 1h a day for 
5 days, behavioural response were checked by an experimental model 
of learning abilities in morris water maze, emotional behavioural 
testing, elevated plus maze and open field. They found some effects of 
moderate intensity SMF on rats.  
 
 Miryam et al., 2009 they perform similar exposure condition on the 
effect of moderate intensity SMF in medulla spinalis. The treatment 
has resulted in variation of ion concentration of medulla spinalis which 
shows Ca2+, Fe+ concentration increased rapidly while no change in 
magnesium and copper. Moderate intensity SMF cause raised blood 
circulation and bone mineral density which is mediated by absorption 
of Ca2+ ion in oesteoblast of bone, this leads to increasing locomotors 
activity. Therefore moderate intensity SMF has analgesic action Kanai 
& Taniguchi studied the influence on experimental rat models. These 
authors suggest that exposure to SMF may induce cholinergic nerves 
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by reducing cholinesterase activity and that results in release of 
acetylcholine induces elevated blood flow.  
 
 A study by Okano and Ohkubo 2005, 2006 investigated the influence 
of combined effect of moderate intensity SMF upto 180mT and 
Nicardipine (Ca2+ channel blocker). The results found that they cause 
significant change in hypertension which can be mediated by clogging 
Ca2+ flux and up regulation of nitrous oxide metabolites. In case of 
animal exposed to magnetic field alone were significantly reduced or 
delayed the hypertensive development. But combined effect of SMF 
and Nicaripine shows increased reduction of blood pressure on rats. 
SMF induces raised NO level in plasma with Nicardipine. The reasons 
beyond these effects were due to elevation of plasma NO 
synergistically with Nicardipine.   
 
 Politanski et al., 2010 conducted the experiments on mouse to 
investigate the effects of noise, when mice exposed to 5mT, 2h a day 
for 2 weeks. The result shows that limited application in hearing.  
Strong Intensity Static Magnetic Field: 
 Tsuji et al., 1996 researched the mice behaviour when exposed to 5T 
for 2 days. They examine weights of major organs in body like kidney, 
brain, heart, liver, spleen and lungs. However measuring the weights of 
major organ after magnetic field exposure shows no significant 
difference on it. But body weight, blood glucose and blood urea 
nitrogen were altered significantly due to fluid shift and also affect 
drinking and eating behaviour due to changes in circadian rhythm by 
exposed SMF. The result showed that SMF affect mice behaviour by 
decrease eating and drinking and lower body weight due to fluid loss 
cause increase blood sugar level and blood urea nitrogen after 2 days. 
Findings of this study show 5T cause direct effect on central nervous 
system.  
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 Prina-Mello et al., 2006 have conducted a study for investigating the 
effectiveness of strong intensity SMF of 1T cause activation of 
intracellular signalling transduction pathways by means of 
Extracellular Regulated Kinase and C-Jun N Terminal Kinase on 
primary cortical neurons were determined. Laszlo and Gyires, 2009 
studied that strong intensity SMF cause alteration in pain response.  
 
 Bhatia, 1999 assessed the strong intensity SMF in mice on 1.4T cause 
some changes in membrane and receptors of primary bone marrow 
cells. In this study temperature dependent effect of magnetic field has 
been observed. Finding shows phagocytic action on bone marrow cell 
mediated by action of body temperature of animal not on sex 
dependent manner. 
  
 Study by Suzuki et al., 2001 investigated that strong intensity SMF on 
mice of 3T, 4.7T for 3 days were influence the alteration in bone 
marrow cells. Because this study is evaluated for wide spread 
application of magnetic resonance imaging, nuclear magnetic 
resonance, electron spin resonance by human beings.  
 
 Okazaki et al., 2001 reported that there were no significant difference 
observed in treated and control group when mice exposed to 4.7T for 
48h. Simultaneously no adverse effects were investigated on fetal 
development. 
Ultra Strong Intensity Static Magnetic Field: 
 Houpt et al., 2007 and 2011 have found the relationship of SMF and 
behaviour of rat using 14.1T, 7T for 30 or 5 min. The behavioural 
change was observed by analysing locomotors activity, food and water 
intake. Decrease in locomotors activity and rearing cause reduction of 
drinking may due to lower mobility. Finally the concluded that high 
strength magnetic field cause reduction of food intake. The result 
showed that ultra strong intensity SMF exposed is directly proportional 
to altering the behavioural response on experimental rat models. 
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 Cason et al., 2006 studied the action of rat for 14T SMF exposed for 
30 min shows behavioural changes. Ichioka et al., 2003 showed that 
decrease in skin temperature were measured. This may due to influence 
in water evaporation when rat exposed to 8T for 5 min. Sekino et al., 
2006 have performed an experiment for describe the effect of SMF on 
rats of 8T for 1ms. The data shows that ultra strong intensity SMF 
cause effects on sciatic nerve potential.  
 
 High et al., 2000 have conducted a study for explaining the effects of 
ultra strong intensity SMF on rat of 9.4T for 10 weeks observed no 
significant changes on spatial memory test, body weight, food and 
water consumption, gross pathological findings, heart rates, terminal 
hematologic, blood biochemical and urine parameters, feeding ratio 
and major organ weights. From the past studies we concluded that ultra 
strong intensity SMF of most of them cause influence in biological 
effect, while some shows no change in bioeffects. 
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AIM AND OBJECTIVE 
Today large number of population suffers from overweight and obesity 
disorder. It has been increasing due to change in life style of community on 
developing and developed countries. An increase in body weight is complex processes 
that results from sedentary life style, lack of physical exercise, particularly 
consumption of energy rich diets are play an important role for its development.  
The primary treatments used for protecting the body weight by diet control 
and exercise. But this is too hard to maintain and also weight regain could be possible. 
Though medication like Orlistat is available but these are having poor outcomes on 
long term weight management and are accompanied with various adverse effects. 
Further, progress in the study of the behavioural and biological manifestations of 
reducing body weight, there is no satisfactory drugs to use in clinical therapy.  
Preventive measures are mostly taken from alternative sources. An alternative 
method of treatment is getting more importance in overweight and obesity because the 
modern medicine does not find curative treatments. 
Currently there are various chemical and physical methods are available 
individually to the treatment of obesity but these methods can effective after long term 
treatment. In this research work we tried to use combination of static magnetic field 
with Metformin in experimental animal model as more effective and enhanced weight 
loss on subacute treatment. This can be obtained by synergism and it’s also safe as the 
strength of glucose and lipid metabolism can be reduced without compromising on 
decreased body weight.  
  The present study will help to improve the biophysical knowledge among the 
researchers on weight loss with lesser side effects, which are affordable, non invasive 
and more effective with safety in the management of overweight and obesity. 
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SCOPE OF WORK 
Scope of this Research Study 
The scope of this research work has been explained under these following 
headings:- 
Reason for targeting this particular disease - overweight and obesity    
Overweight and Obesity is a health condition in which the body weight is 
persistently elevated (high BMI). Persistent increase in body weight is one of the risk 
factors for type 2 diabetes, hypertension, cardiovascular disorders, dyslipidemia and 
certain types of cancers. Even moderate elevation of body weight leads to shortened 
life expectancy.  
The World health statistics 2013 report that one-third of world’s population 
was overweight and obese. According to WHO 2015, shows that there are at least 2.3 
billion peoples will be overweight and more than 700 million people worldwide who 
have elevated BMI (obese). In the developed countries like United States, shows 
about 13% of people have elevated BMI of world’s obese population, while India and 
China together accounted for 15% of world’s obese population. The WHO rates 
overweight and obese as one of the most important causes of premature death 
worldwide and the problem is growing.  
Obesity is a risk factor for diabetes and the single most important risk factor 
for type 2 diabetes. It causes about 90% of obese individuals where increases the risk 
of type 2 diabetes. In addition to type 2 diabetes, complications of overweight and 
obesity includes dyslipidaemia, NAFLD, certain types of cancer, hypertension, 
coronary heart diseases and stroke.  
The condition is often associated with significant morbidity and mortality. 
Because of this, it is one of the most significantly under-diagnosed and undertreated 
medical conditions.  
 
 
SCOPE OF WORK 
 
Department of Pharmacology, NCP Page 23 
 
Reason for choosing magnetic field and oral hypoglycemic agent for overweight 
and obesity 
Overweight and obesity is one of the most pandemic disease states in the 
world today, and chronic, life-long drug therapy is often required for the maintenance 
of acceptable body weight levels. Diet and physical exercise are a first line treatment 
for overweight and obesity, as they reduce calorie intake and increase utilization of 
calories, thereby lowering elevated body weight, without exhibiting serious-adverse 
effects. But their maintenance in reducing body weight is difficult and weight regain 
is possible once discontinue the treatment. 
Permanent/SMF, PEMF, low frequency electromagnetic field and transcranial 
magnetic field are used widely, not only for bone disorders, but also for the treatment 
of disease states such as parkinson’s disease, Alzheimer’s disease and hemiplegia. 
They are effective alternative medications with generally safe use. 
Development of SMF of moderate intensity considered beneficial in terms of 
lowering the elevated body weight, with the aim of improving patient compliance and 
subsequent therapeutic outcomes.  
Oral hypoglycemic agent of certain types shows significant lowering of 
elevated body weight on their treatment. In addition to that other types were not 
shows significant alteration in body weight were reported. 
Reason for choosing a moderate intensity SMF and Metformin 
Moderate intensity comes under second types of SMF which exhibits the 
highest degree of reducing body weight compared to other SMF, while strong 
intensity have an less action on decreasing body weight but low intensity and ultra 
high intensity being completely have no action on body weight. 
Moderate intensity is a selective SMF for the treatment of mild and moderate 
elevated body weight and also for long term management. Moderate intensity SMF is 
one such magnetic field that is used for the treatment of several disorders. It may be 
used alone or in combination with western medicine. The magnetic field is generally 
exposed alone or combination therapy for enhancing its action. These causes decrease 
the cost of treatment and make patient convenience with highly effective and safety. 
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Therefore, moderate intensity SMF is an ideal magnetic field candidate for magnetic 
field treatment.  
Metformin is a well tolerated oral hypoglycemic agent which is used for first 
line treatment of Type 2 diabetes and not cause severe hypoglycemic on overdose. 
Past decade’s Metformin shows significant weight loss in non diabetic obese person 
were reported. Hence we are aimed to doing research on combined effect of SMF and 
Metformin for examine its synergetic action of decreasing body weight in HFD 
induced overweight rats. 
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PLAN OF WORK 
This research works was carried out as under:- 
 Exhaustive literature survey 
 Computational modelling and simulation 
 Selection and maintenance of animal  
 Ethical consideration 
 Experimental induction of overweight  
 Design of Static Magnetic Field device 
 Static Magnetic Field and Metformin treatment 
 Pharmacological evaluation 
Anti-obesity activity 
 Determination of blood glucose level (mg/dl) 
 Parameter measured 
 Body weight(gm) 
 Food intake (gm)  
 Water intake (ml) 
 Body temperature (◦C) 
 Determination of Locomotor activity 
 Estimation of biochemical parameters: 
 SGOT, SGPT, ALP (IU/l) 
 TC, TG, LDL, VLDL, HDL (mg/dl) 
 
 Statistical analysis  
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MATERIALS AND METHODS 
Computational modelling and simulation 
Computational modelling and simulation of moderate intensity SMF exposure 
system prior to actual practical design and development process is very essential for 
designing flexibility and efficiency. 3-D Ansys Maxwell engineering software, 2014 
version was used for modelling and simulation of SMF exposure device. This has 
been utilised to computationally model and simulate permanent magnetic field 
exposure system for most effective uniform distribution of magnetic flux density. Our 
model has utilised 2D application mode which present in this software.  
Figure 1: Computational modelling and simulation of moderate intensity 
SMF 
 
 Permanent magnet plate made of alnico material could be modelled and 
designed for investigation of rectangular shape with dimension of 137mm length, 
80mm width, and 8mm thickness. Two rectangular magnetic plates of previously 
mentioned parameters to be placed between gap of 300mm on rectangular rat cage of 
dimension 415mm length, 262mm width and 165mm height. By establishing the 
geometric model, setting boundary conditions and obtaining numerical solutions. We 
can find that the magnetic flux density on rat behavioural palne (XY plane) was 
uniform and the peak magnetic field intensity of average about 128mT was observed. 
The reason for selecting this particular moderate intensity SMF was that it had been 
reported to be effective in weight reducing on whole body which were performed by 
our study group over a short period of time. 
MATERIALS AND METHODS 
 
Department of Pharmacology, NCP Page 27 
 
Selection and maintenance of animals 
Totally thirty male Wistar albino rats of 60 days age weighing between 150 - 
180 g were used for this study. The animals were checked for disease, only healthy 
rodent is accepted for the experiments. The animals were obtained from the animal 
house of Nandha College of Pharmacy, Erode-52, Tamil Nadu, India. Animals were 
randomly grouped in polypropylene cages with paddy husk as bedding. A temperature 
of 25±2 ˚C and relative humidity of 30-70% was maintained. A 12 hours light and 12 
hours dark cycle were strictly followed. All the animals were allowed to free access to 
water and fed with standard commercial pelleted rat chaw (M/s. Hindustan Lever Ltd., 
Mumbai). All the experimental procedures and protocols used in this study were 
reviewed by the Institutional Animal Ethics Committee (Reg No: 
688/PO/Re/S/02/CPCSEA) of Nandha College of Pharmacy, Erode-52 and were 
accordance with the guidelines of the IAEC.  
Ethical consideration 
The study was conducted after obtaining the approval from Committee for the 
Purpose of Control and Supervision of Experiments on Animals (CPCSEA) and 
Institutional Animal Ethics Committee (IAEC), proposal number NCP/IAEC/2016-
2017-01. 
Experimental induction of overweight 
The acclimatized animals were checked for initial body weight and then 
animals subjected to increasing body weight were fed with HFD composition of 60% 
Kcal fat, 20% Kcal carbohydrate and 20% Kcal protein and rest of animals were fed 
with Standard Diet (SD). After 14 days rats which consuming HFD with body weight 
of 250 gm or above to be included in the study. HFD induces increasing body weight 
in laboratory animals. 
Composition of High Fat Diet 
Casein (20%) - 200 gm; Starch - 425 gm; Sucrose - 100 gm; Cellulose - 50 
gm; Ground Nut oil - 175 gm; Mineral mix - 35 gm; Vitamin Mix - 10 gm; L-Cystine 
- 3 gm; Choline - 2 gm (Sivakumar et al., 2016). 
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Design of Static Magnetic Field device: 
  The SMF exposure device (Length: 137mm; Height: 80mm; Width: 8mm) was 
composed of a pair of rectangular magnetic plates made by alnico material, internally 
placed parallel to each other and at the air gap of 30 cm from two sides of standard rat 
cage (Length: 415 mm, Height: 165 mm, Width: 262 mm). The mean flux density at 
the centre of a cage was 128 mT (range = 125 - 132mT), respectively.  
Static Magnetic Field treatment: 
After confirmation of increased body weight the overweight rats were divided 
into different groups as mentioned below. 
Grouping of animals: 
Group I : Normal control (SD + 0.5% NaCMC 10ml/kg, p.o) 
Group II : Negative control (HFD + 0.5% NaCMC 10ml/kg, p.o) 
Group III : Positive control (HFD + Orlistat  200mg/kg/day, p.o) 
Group IV : Test I (HFD + Metformin 20mg/kg/day, p.o) 
Group V : Test II (HFD + SMF 128 mT/ hr/day + 0.5% NaCMC,10ml/kg, p.o) 
Group VI : Test III (HFD + SMF 128 mT/hr/day + Metformin 20mg/kg/day, p.o)   
The drug was dissolved in 0.5% NaCMC and administered orally via a 
standard orogastric cannula, then animals to be exposed to magnetic field could 
placed in static magnetic field exposure device.   
PHARMACOLOGICAL EVALUATION 
Anti-Obesity Activity 
Determination of blood glucose level (Lahbib et al., 2010) 
Blood samples were collected from the tip of the tail vein on initial day, 7th 
day and 15th day from tail vein by snipping off the tip of the tail and the blood 
glucose was measured by a glucometer (Accu-Chek active Roche, Switzerland). 
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Parameters Measured (Dixit et. al., 2012) 
Body weight 
The body weight (gm) was recorded on day 1 and then on alternate days for 15 
days in High Fat Diet induced overweight rats. 
Food and water intake 
 The daily food and water intake was measured for 15 days in HFD induced 
overweight rats in each groups on cage basis. 
Body temperature 
 The body temperature was recorded on day 14 in HFD induced overweight 
rats using rectal telethermometer before and after treatment at 30, 60, 90 and 120 min 
time interval with contact time of 1 min. 
Determination of Locomotor Activity (Dixit et. al., 2012) 
 Locomotor activity was recorded on day 14 in HFD induced overweight rats. 
Each rat was placed individually in the actophotometer with 10 min observation time 
after treatment and basal activity score was obtained. The movement of the animal 
cuts off a beam of light falling on the photocell and a count was recorded and 
displayed digitally.  
Estimation of Biochemical Parameters (Sivakumar et al., 2016) 
The biochemical parameters were determined after 24 hour of the last dose of 
treatment. On day 15 of experimentation, blood was withdrawn from retro-orbital 
plexus under pentobarbitone sodium (50mg/kg/i.p) anaesthesia and then blood 
samples were allowed to clot for room temperature. Serum was separated by 
centrifugation at 3000 rpm at room temperature for 15 minutes and utilized for 
estimation of biochemical parameters including serum lipid profile, Serum Glutamate 
Oxaloacetate Transaminase (SGOT), Serum Glutamate Pyruvate Transaminase 
(SGPT) and Alkaline Phosphatase (ALP). Lipid profile like Total cholesterol, 
Triglyceride, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), and 
Very Low Density Lipoprotein (VLDL) levels were measured from serum sample by 
using the biochemical kits (Span diagnostic Ltd, Mumbai, India). 
MATERIALS AND METHODS 
 
Department of Pharmacology, NCP Page 30 
 
Serum Glutamate Oxaloacetate Transaminase (Tietz and Saunders, 1997) 
Principle  
Aspartate amino transferase (AST) catalyses the transamination of L-Aspartate 
and α-Keto glutrate to form oxaloacetate and L-Glutamate. Oxaloacetate so formed is 
coupled with 2, 4-dinitrophenyl hydrazine (2,4-DNPH) to form a corresponding 
hydrazone, a brown coloured complex in alkaline medium and this can be measured 
calorimetrically.  
Procedure  
SGOT in serum was estimated by MOD-IFCC method using an Asritha 
diagnostic kit. Pipetted out the serum sample in to clean dry test tube labeled as test. 
The test sample tube containing working reagent and serum sample. Mixed well and 
the initial absorbance after 1 min at 340nm was checked and repeated the absorbance 
reading after 1,2 & 3 min. calculate the mean absorbance changed per minute.  
Calculation : SGOT activity in U/L 37oC = ΔA/min×1746×Tf  
Serum Glutamate Pyruvate Transaminase (Wolf et al., 1972) 
Principle  
Alanine amino transferases (ALT) catalyses the transamination of L-Alanine 
and α- Ketoglutarate to form pyruvate and L- glutamate. Pyruvate so formed is 
coupled with 2,4-dinitro phenyl hydrazine (2,4 DNPH) to form a corresponding 
hydrazone, a brown colour complex in alkaline medium and this can be measured 
colorimetrically.  
Procedure  
SGPT in serum was estimated by MOD-IFCC method using an Asritha 
diagnostic kit. Pipetted out the serum sample in to clean dry test tube labeled as test. 
The test sample tube containing working reagent and serum sample. Incubated at the 
assay temperature for 1 min at 340 nm then added sample (serum). Mix well and read 
the initial absorbance after 1 min and repeated the absorbance changed per min 
(ΔA/min.).  
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Calculation :SGPT activity in U/L 37oC=ΔA/min×1746.  
Alkaline Phosphatase (Wilkinsons and Winsten, 1969) 
Principle  
Alkaline phosphatase from serum converts phenyl phosphate to inorganic 
phosphate and phenol at pH 10.0. Phenyl so formed reacts in alkaline medium with 4-
aminoantipyrine I presence of the oxidizing agent Potassium ferricyanide and forms 
an orange red coloured complex, which can be measured calorimetrically. The colour 
intensity is proportional to the enzyme activity.  
Procedure  
ALP in serum was estimated by PNPP method using an Asritha Diagnostic 
Kit. Pipetted out the serum sample into a clean dry test tube labeled as test. The test 
The test sample tube containing working reagent and serum sample. Mixed well and 
the initial absorbance after 1 min at 340nm was checked and repeated the absorbance 
reading after 1,2 & 3 min. Calculate the mean absorbance changed per minute.  
Calculation : ALP activity in U/L 37oC = ΔA/min×275×Tf  
Lipid profile: 
Total cholesterol (Roeschlau et al., 1974) 
Total cholesterol in serum was determined by a colorimetric method. The 
assay principle is based on enzymatic hydrolysis and oxidation of cholesterol and the 
indicator compound, quinoneimine is formed from hydrogen peroxide and 4-
aminoantipyrine in the presence of phenol and peroxidase. The reagents consisted of 
4-aminoantipyrine (0.03 mmol/l), phenol (6 mmol/l), peroxidase (≥0.5 U/ml), 
cholesterol esterase (> 0.15 U/ml), cholesterol oxidase(> 0.1 U/ml) and pipes buffer 
(80 mmol/L pH 6.8). The serum sample (10 μl) was mixed with 1 ml of reagent, 
incubated at 37oC for 5 min, and absorbance measured at 500 nm against the reagent 
blank. The cholesterol standard was 5.17 mmol/l (200 mg/dl). The concentration of 
total cholesterol in the sample was calculated by  
Total cholesterol = ΔA sample/ ΔA standard x concentration of standard.  
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Triglycerides (Tietz, 1990) 
Serum Triglycerides (TG) were determined by a colorimetric method. The 
assay principle is based on the enzymatic hydrolysis of TG with lipases and the 
indicator is a quinoneimine formed from hydrogen-peroxide, 4-aminophenazone and 
4-chlorophenol under the catalytic activity of peroxidase. The enzyme reagent 
consisted of 4-aminophenazone (0.5 mmol/l), ATP (1.0 m.mol/l), lipases (≥150 
U/ml), glycerol-kinase (≥0.4 U/ml), glycerol-3-phosphate oxidase (≥1.5 U/ml), 
peroxidase (≥0.5 u/ml). The serum sample (10 μl) was mixed with 1000 μl of enzyme 
reagent, incubated at 37oC for 5 min and absorbance measured at 500 nm against the 
reagent blank. The TG standard was 200 mg/dl (2.29 mmol/l). The concentration of 
TG in the serum was calculated by  
Triglycerides = ΔA sample / ΔA standard x concentration of standard.  
HDL (Lopes-Virella et al., 1977) 
Serum HDL cholesterol was determined by a colorimetric method.  The assay 
principle is based on the following: the Low Density Lipoproteins (LDL and VLDL) 
and chylomicron fraction is precipitated quantitatively by the addition of 
phophotungstic acid in the presence of magnesium ions. After centrifugation, the 
cholesterol concentration in the HDL fraction, which remains in the supernatant, is 
determined. The precipitation reagents consisted of phosphotungstic acid (0.55 
mmol/l) and magnesium chloride (25 mmol/l). The serum sample (200 μl) was mixed 
with 500 μl of precipitation reagent and centrifuged at 4000 rpm for 10 min. The 
supernatant (100 μl) was mixed with reagent (CH 200 1 ml), incubated at 37oC for 5 
min and absorbance measured at 500 nm against the reagent blank. The cholesterol 
standard was 200 mg/dL (5.17 mmol/l). The concentration of cholesterol in the 
supernatant was calculated by. 
HDL = ΔA sample / ΔA standard x concentration of standard.  
LDL & VLDL (Friedewald et al., 1972) 
Low Density Lipoprotein (LDL) and Very Low Density Lipoprotein (VLDL) 
were calculated according to Friedwald formula. 
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LDL = TC – HDL – VLDL  
VLDL = Triglycerides / 5.  
STATISTICAL ANALYSIS  
Results were expressed as mean ± SEM. Statistical analysis was carried out 
using one way Analysis of Variance (ANOVA) followed by Dunnett’s ‘t’ test.            
P value <0.05 was considered as significant. 
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RESULTS 
Table 4: Effect of Static Magnetic Field and Metformin on fasting blood glucose 
(mg/dl) level in control and experimental rats 
 
Groups 
 
 
Initial Day 
 
7th day 
 
15th day 
 
Standard Diet 
 
89.00±1.14 90.00±1.09 88.00±0.84 
 
HFD Overweight Rat 
 
120.00±5.00 115.00±4.40 128.00±2.24 
 
HFD + Orlistat  
(40 mg/kg) 
 
108.00±4.64 105.00±1.70 108.00±1.70 
 
HFD + Metformin  
(200 mg/kg) 
 
120.00±4.40 111.00±1.30 118.00±5.00 
 
HFD + SMF  
(128 mT/hr/day) 
 
125.00±4.40 140.00±2.98* 160.00±2.98*** 
 
HFD + SMF 
(128 mT/hr/day) + 
Metformin (200 mg/kg) 
 
130.00±2.45* 110.00±1.84 105.00±1.84 
 
The Data Represented as mean ±SEM (n=5) 
*P<0.05, **P<0.01 and ***P<0.001 Vs Induced Control 
 
The blood glucose levels measured in normal and experimental rats in initial 
and at the 7th and 15th days of treatment are given in Table 4 and Figure 2. HFD 
induced overweight rats showed significant increase in the levels on blood glucose as 
compared to SD fed rats. Oral administration of Orlistat (40 mg/kg) and Metformin 
(200 mg/kg) shows no significant change in blood glucose level, while the SMF (128 
mT/hr/day) exposed group shows a significant increase (p<0.05), (p<0.001) in blood 
glucose levels and Oral administration of Metformin (200 mg/kg) with SMF (128 
mT/hr/day) exposed group shows a significant decrease (p<0.05) in blood glucose. 
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Figure 2: Effect of Static Magnetic Field and 
Metformin on fasting blood glucose level in control 
and experimental rats 
 
Standard Diet
HFD
HFD + Orlistat
HFD + Metformin
HFD + SMF
HFD + SMF +
Metformin
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Table 5: Effect of Static Magnetic Field and Metformin on body weight (gm) changes in control and experimental rats 
 
The Data Represented as mean ±SEM (n=5) 
*P<0.05, **P<0.01 and ***P<0.001 Vs Induced Control 
Groups 
 
Initial Day 
 
3rd Day 5th Day 7th Day 9th Day 11th Day 13th Day 15th Day 
 
Standard Diet 
 
160±3.54 155±5.00 160±3.54 165±3.54 165.4±3.20 170.40±3.74 175±3.54 180±4.40 
 
HFD 
Overweight Rat 
255±1.84 260±1.58 270±5.38 280±3.86 280.0±4.40 285.00±6.36 290±6.70 295±5.33 
 
HFD + Orlistat 
(40 mg/kg) 
260±3.54 255±1.84 240±1.84* 230±1.84** 235.0±1.87** 240.00±1.84* 240±1.70* 235±1.87** 
 
HFD + 
Metformin (200 
mg/kg) 
270±5.38 275±3.52 269±6.00 265±5.24 265.0±5.78 269.00±6.00 260±5.24 260±5.47 
 
HFD + SMF 
(128 mT/hr/day) 
265±5.00 260±5.24 260±5.24 258±1.22* 255.0±5.00* 250.00±4.78* 255±5.00* 255±5.00* 
 
HFD + SMF 
(128 mT/hr/day) 
+ Metformin 
(200 mg/kg) 
258±1.38 263±1.55 258±1.38* 255±5.00* 250.0±4.78* 250.00±5.09* 245±1.84** 243±2.93** 
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Table 5 and Figure 3 depicts the body weight changes of different groups of 
rats during the experimental period. HFD induced over weight rats showed that 
significant increase in body weight throughout the experimental period when 
compared to SD fed rats. Administration of Orlistat (40 mg/kg), SMF (128 
mT/hr/day), SMF (128 mT/hr/day) with Metformin (200 mg/kg) shows decrease in 
body weight. While oral administration of Metformin (200 mg/kg) shows no 
significant change in body weight.  On comparing the weight loss of SMF (128 
mT/hr/day) treated animals the group SMF with Metformin (200 mg/kg) animals were 
found to be significant (p<0.05, p<0.01). 
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Figure 3: Effect of Static Magnetic Field and 
Metformin on body weight changes in control and 
experimental rats 
 
Standard Diet
HFD
HFD + Orlistat
HFD +
Metformin
HFD + SMF
HFD + SMF +
Metformin
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Table 6:  Effect of Static Magnetic Field and Metformin on food and water 
intake and body temperature in control and experimental rats 
 
 
Groups 
 
Food intake 
(gm) 
Water intake 
(ml) 
 
Body temperature 
(◦C) 
 
Standard Diet 85.69±0.81 170.00±1.31 
 
33.20±0.002 
 
 
HFD Overweight 
Rat 
 
122.08±1.31 175.00±1.44 33.61±0.007 
 
HFD + Orlistat (40 
mg/kg) 
 
110.00±1.86 172.00±1.44 33.34±0.007 
 
HFD + Metformin 
(200 mg/kg) 
 
117.46±9.07 175.85±1.63 33.52±0.007 
 
HFD + SMF (128 
mT/hr/day) 
 
119.92±2.36 172.85±1.63 33.43±0.010 
 
HFD + SMF(128 
mT/hr/day) + 
Metformin (200 
mg/kg) 
 
115.15±2.23 171.85±1.63 33.40±0.008 
The Data Represented as mean ±SEM (n=5) 
*P<0.05, **P<0.01 and ***P<0.001 Vs Induced Control 
 
The food and water intake, body temperature were measured in normal and 
experimental rats of treatment are given in Table 6 and Figure 4. HFD induced 
overweight rats showed no significant change in food and water intake, body 
temperature on compared to SD fed rats. Oral administration of  Orlistat (40 mg/kg) 
and Metformin (200 mg/kg), SMF (128 mT/hr/day) exposed group and  Oral 
administration of Metformin (200 mg/kg) with SMF (128 mT/hr/day) exposed group 
also shows no significant change in food and water intake, body temperature on 
compared to HFD overweight rat. 
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Figure 4: Effect of Static Magnetic Field and 
Metformin on food and water intake and body 
temperature in control and experimental rats 
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Body 
Temperature 
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Table 7:Effect of Static magnetic field and Metformin on locomotor activity in 
control and experimental rats 
 
 
Groups 
 
 
Locomotors activity 
14th Day 
 
 
Standard Diet 
 
150.00±3.62 
 
HFD Overweight Rat 
 
89.00±1.76 
 
HFD + Orlistat 
(40 mg/kg) 
 
130.00±1.70** 
 
HFD + Metformin 
(200 mg/kg) 
 
95.00±4.66 
 
HFD + SMF 
(128 mT/hr/day) 
 
98.00±1.41 
 
HFD + SMF 
(128 mT/hr/day) + 
Metformin (200 mg/kg) 
 
115.00±2.98** 
 
The Data Represented as mean ±SEM (n=5) 
*P<0.05, **P<0.01 and ***P<0.001 Vs Induced Control 
 
The locomotor activity is measured in normal and experimental rats of 
treatment are given in Table 7 and  Figure 5. HFD induced overweight rats showed 
significant decrease (P<0.05) in  locomotor activity on compared to SD fed rats. Oral 
administration of  Orlistat (40 mg/kg) and  Oral administration of Metformin (200 
mg/kg) with SMF (128 mT/hr/day) exposed group shows significant increase 
(P<0.01) in locomotor activity while Oral administration of Metformin (200 mg/kg) 
and SMF (128 mT/hr/day) exposed group showed no significant change in locomotor 
activty on compared to HFD overweight rat. 
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Figure 5: Effect of Static Magnetic Field and 
Metformin on locomotor activity in control and 
experimental rats 
Locomotor Activity
RESULTS 
 
Department of Pharmacology, NCP Page 42 
 
Table 8: Effect of Static Magnetic Field and Metformin on liver function 
parameters (IU/L) in control and experimental rats. 
 
 
The Data Represented as mean ±SEM (n=5) 
*P<0.05, **P<0.01 and ***P<0.001 Vs Induced Control 
 
The above table 8 and figure 6 depicts the Serum levels of SGOT, SGPT, and 
ALP. The liver enzyme level found to increases in the HFD induced overweight rats. 
But on treatment with the standard Orlistat (40 mg/kg) the value of the enzyme level 
reduced to marked level. On treatment with SMF (128 mT/hr/day)  with Metformin 
(200 mg/kg) the level of the enzyme reduced significantly (P<0.05, p<0.01) when 
compared to individual treatment of Metformin (200 mg/kg) and SMF (128 
mT/hr/day). The levels of these found to be normal in group I normal control. But it 
 
GROUPS 
 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
ALP 
(IU/L) 
 
Standard Diet 
 
40.00±0.61 37.00±1.04 125.00±0.69 
 
HFD Overweight Rat 
 
52.00±0.40 40.00±0.65 
 
160.00±1.34 
 
 
HFD + Orlistat 
(40 mg/kg) 
 
42.00±0.61 38.00±1.72 129.00±0.89** 
 
HFD + Metformin 
(200 mg/kg) 
 
49.98±0.34 42.00±0.67 140.00±1.68* 
 
HFD + SMF 
(128 mT/hr/day) 
 
49.00±0.35 39.00±0.53 134.00±0.92** 
 
HFD + SMF 
(128 mT/hr/day) + 
Metformin (200 mg/kg) 
 
45.00±1.40 38.50±1.71 132.00±0.48** 
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found to be increased in HFD induced overweight group (II). On comparison with 
HFD Overweight rats the levels of ALP, found to decrease significantly (p<0.01) in 
SMF (128 mT/hr/day) with Metformin (200 mg/kg) group. 
 In case of SGOT and SGPT the value found to increase in HFD induced 
overweight group (II) on comparing with SD fed rats. On treatment with Orlistat (40 
mg/kg) SGOT and SGPT levels in serum founds to decrease. Similarly the treatment 
with Metformin (200 mg/kg), SMF(128 mT/hr/day), SMF(128 mT/hr/day)  with 
Metformin (200 mg/kg)  also improves the level of SGOT and SGPT in test group (IV 
,V an VI). 
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Figure 6: Effect of Static Magnetic Field and 
Metformin on liver function parameters in control 
and experimental rats 
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Table 9: Effect of Static Magnetic Field and Metformin on lipid profile (mg/dl) in control and experimental rats 
 
 
Group 
 
Total 
Cholesterol 
(mg/dl) 
Triglycerides 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dl) 
HDL 
(mg/dl) 
 
Standard Diet 
 
67.00±0.43 77.00±0.40 27.00±0.34 15.00±0.54 29.50±1.19 
 
HFD Overweight Rat 
 
77.00±0.40 190.00±0.53 37.00±0.38 19.00±0.80 28.00±0.63 
 
HFD+Orlistat (40 mg/kg) 
 
68.00±0.54 108.00±0.86 30.00±0.34 15.60±0.34 29.10±0.39 
 
HFD+Metformin  
(200 mg/kg) 
 
69.00±0.54 229.00±0.85* 35.00±0.57 18.50±0.80 29.20±1.09 
 
HFD+SMF  
(128 mT/hr/day) 
 
50.00±2.99* 107.00±0.86** 34.20±0.63 17.00±0.80 28.50±0.29 
 
HFD+SMF (128 mT/hr/day) 
+ Metformin (200 mg/kg) 
 
67.00±2.16 152.00±0.70* 33.00±0.87 16.50±0.80 29.00±0.38 
The Data Represented as mean ±SEM (n=5) 
*P<0.05, **P<0.01 and ***P<0.001 Vs Induced Control
RESULTS 
 
Department of Pharmacology, NCP Page 45 
 
The levels of Total Cholesterol, Triglycerides, LDL and VLDL tend to rise in 
HFD induced overweight rats. The level reaches its maximum in HFD overweight rats 
group. But the condition was overcome in Orlistat (40 mg/kg), Metformin (200 
mg/kg), SMF (128 mT/hr/day) and SMF (128 mT/hr/day) with Metformin (200 
mg/kg) treated animals. The effect of decrease in lipid parameters was found to be 
significant (p<0.01) in the SMF (128 mT/hr/day) treated animals.  
In case of HDL the value decreases in HFD overweight rats on comparing to 
Standard diet group. This effect was reversed in Orlistat (40 mg/kg), Metformin (200 
mg/kg), SMF (128 mT/hr/day) and SMF (128 mT/hr/day) with Metformin (200 
mg/kg) treated animals.  
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Figure 7: Effect of Static Magnetic Field and 
Metformin on lipid profile in control and 
experimental rats  
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SUMMARY AND DISCUSSION 
The present thesis entitled “Combined Effect of Static Magnetic Field and 
Metformin on Weight Loss In Overweight Rats” deals with the exploration of 
pharmacological screening of Magnetic Field with Metformin. On past two decades 
Magnetic field is used for treating Bone disorders and Nerve disorders. The results 
obtained from using magnetic field by various researchers were shown in the table 3.1 
and 3.2. The SMF exposure device was fabricated by using 3-D Ansys Maxwell 
engineering software, 2014 version. Approval was obtained from Committee for the 
Purpose of Control and Supervision of Experiments on Animals (CPCSEA) and 
Institutional Animal Ethics Committee (IAEC), proposal number NCP/IAEC/2016-2017-
01. 
Consumption of a diet rich in calories in the form of sugars and fats and its 
accumulation in most part of the body leads to excessive growth of adipose tissue, 
chronic inflammation, and metabolic perturbations. It can also lead to the development of 
hyperlipidemia, atherosclerosis and abnormal lipid metabolism (Onody et al., 2003). 
Epidemiological studies recommended that excess dietary energy intake is one of the 
frequent causes of obesity (Lee et. al., 2008 and Bhandari et. al., 2011). In the present 
study, the effects of SMF with Metformin on the alterations of glucose, liver parameter 
and lipid profile in high-fat diet (HFD) rats were investigated. Our earlier studies 
indicated that the rats fed with HFD showed significant increase in body weight, plasma 
glucose, insulin, and leptin, which leads to complications clinically (Sudhakara et al., 
2014). 
The animals were grouped into Group 1 (SD Control) Group 2 (HFD control), 
Group 3 (HFD + Orlistat 40 mg/kg/day/po for 2 weeks), Group 4 (HFD + Static 
Magnetic Field 128 mT/1h/day for 2 weeks), Group 5 (HFD + Metformin 200 
mg/kg/day/po for 2 weeks), Group 6 (HFD + Static Magnetic Field 128 mT/1h/day with 
Metformin 200 mg/kg/day/po for 2 weeks). 
In case of blood glucose level the drastic increase in glucose levels was due to the 
release of the hyperglycemic hormone (glucagon) or the inhibition of the hypoglycemic 
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hormone (insulin) as previously shown by Lahbib, et al., 2010 and also due to 
conformational change of insulin was observed by Elferchichi et al., 2011, this leads to 
decreasing the binding capacity of insulin. The elevated glucose level in blood was 
reversed by treatment with Combined SMF with Metformin. This may be possibly due to 
the insulin like effect of SMF with Metformin on peripheral tissues, either by promoting 
glucose uptake and metabolism or by inhibiting hepatic gluconeogenesis. 
Treatment with SMF resulted in reduction in body weight indicating that SMF 
posess weight reducing property. The decreasing body weight might due to decrease in 
body fluid and protein content or other factor including hormonal changes (Lahbib, et al., 
2010). In the present study, the result showed that no significant change in food and 
water intake and body temperature was observed on treatment with combined SMF and 
Metformin. Nevertheless, the body weight decrease could not be related to dehydration 
but probably due to hypoxia status known to alter the body weight (Amara et. al., 2006). 
Locomotor activity could be decreased in HFD induced rats were observed in this study. 
In addition to that, Increased locomotor activity were observed on treatment with 
combined SMF and Metformin. This may be due to decreasing in body weight with 
improving the functions of sciatic nerve. Previous study reported by Sekinz et al., 2006 
shows alteration in sciatic nerve function on exposing SMF. 
Serum liver biomarkers (SGOT and SGPT) are important criteria for the 
evaluation of liver toxicity. The amounts of enzymes that leak into the blood stream 
indicate severity of hepatic damage. In the present study, the serum liver function 
parameters such as SGOT, SGPT and ALP were increased significantly in HFD induced 
rats indicate that the hepatic injury was induced by HFD induced obesity. The increased 
serum levels of SGOT and SGPT were due to the damage in structural integrity of liver, 
since these enzymes are normally located in the cytoplasm and released into the 
circulation after cellular injury. Along with SGOT and SGPT, the other biomarkers for 
liver damage are ALP was also increased in HFD treated groups. The liver function 
parameters were significantly decreased after the post treatment of Metformin and its 
combination with SMF therapy only while increased levels were observed in SMF alone 
group (Sivakumar et al., 2016).  
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The most common lipid abnormalities in overweight rats are hypertriglyceridemia 
and hypercholesterolemia. Administration of the SMF with Metformin decreases 
hypertriglyceridemia and hypercholesterolemia significantly (P<0.01). The observed 
hypolipidemic effect may be due to decreased cholesterologenesis and fatty acid 
synthesis. HDL cholesterol level was significantly improved by the combined SMF with 
Metformin treatment.  
                                                                                                               CONCLUSION 
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CONCLUSION 
This study entitled “Combined effect of Static Magnetic Field and Metformin 
on weight loss in overweight rats” shows a potential antiobesity activity and could 
protect the body against glucose, liver and lipid parameters related to obesity and its 
complications. Thus confirming its general use in medical practice to cure and manage 
body weight. There is a need for further investigation to evaluate the exact mechanism 
for biochemical activity in order to confirm which are responsible for antiobesity. 
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